Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial
- PMID: 26479973
- DOI: 10.1097/INF.0000000000000965
Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial
Abstract
Background: The quadrivalent meningococcal glycoconjugate vaccine MenACWY-CRM is licensed for children from 2 months of age as a 4-dose series. This study assessed the immunogenicity of a 3-dose MenACWY-CRM vaccination series in infants, compared with the 4-dose series, and evaluated the impact of MenACWY-CRM concomitant administration on immune responses to the 13-valent pneumococcal conjugate vaccine (PCV13).
Methods: Overall, 751 healthy infants (age: 55-89 days) were randomized to receive 3 or 4 doses of MenACWY-CRM (2/4/12 or 2/4/6/12 months of age, respectively) with PCV13 + routine vaccinations (ACWY3 and ACWY4 groups, respectively) or PCV13 + routine vaccinations only (routine group). Immunological noninferiority of the 3-dose versus 4-dose MenACWY-CRM vaccination series was evaluated at 13 months of age for serogroups CWY; noninferiority of immune responses to PCV13 serotypes for concomitant administration of MenACWY-CRM and PCV13 was evaluated at 7 and 13 months of age.
Results: At 13 months, 88%-100% of subjects in groups ACWY3 and ACWY4 achieved seroprotective bactericidal antibody titers against serogroups ACWY; noninferiority criteria for the 3-dose versus 4-dose MenACWY-CRM vaccination series were met. At 7 months, noninferiority criteria were met for all PCV13 serotypes except for serotypes 3 and 5 (group ACWY3) and 19A (group ACWY4). At 13 months, noninferiority criteria were met for all PCV13 serotypes for both ACWY groups.
Conclusions: After completion of either MenACWY-CRM vaccination series, most subjects achieved seroprotective titers against serogroups ACWY, with the 3-dose series being noninferior to the 4-dose series for serogroups CWY, and no interference with immune responses against PCV13 serotypes was observed (NCT01214837).
Similar articles
-
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1. Vaccine. 2013. PMID: 24004465 Clinical Trial.
-
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.Pediatr Infect Dis J. 2012 Jan;31(1):64-71. doi: 10.1097/INF.0b013e31823dce5c. Pediatr Infect Dis J. 2012. PMID: 22094635 Clinical Trial.
-
Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4. Vaccine. 2014. PMID: 24397906 Clinical Trial.
-
An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.Expert Rev Vaccines. 2018 Oct;17(10):865-880. doi: 10.1080/14760584.2018.1521280. Epub 2018 Sep 27. Expert Rev Vaccines. 2018. PMID: 30198805 Review.
-
Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Expert Rev Vaccines. 2011 Jan;10(1):21-33. doi: 10.1586/erv.10.147. Expert Rev Vaccines. 2011. PMID: 21162617 Review.
Cited by
-
[Health Technology Assessment (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy].J Prev Med Hyg. 2021 May 13;62(1 Suppl 1):E1-E128. doi: 10.15167/2421-4248/jpmh2021.62.1s1. eCollection 2021 Mar. J Prev Med Hyg. 2021. PMID: 34622076 Free PMC article. Italian. No abstract available.
-
A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.Infect Dis Ther. 2022 Apr;11(2):639-655. doi: 10.1007/s40121-021-00519-2. Infect Dis Ther. 2022. PMID: 34591258 Free PMC article. Review.
-
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.Hum Vaccin Immunother. 2021 Nov 2;17(11):4689-4700. doi: 10.1080/21645515.2021.1968214. Epub 2021 Sep 28. Hum Vaccin Immunother. 2021. PMID: 34582323 Free PMC article. Clinical Trial.
-
Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.Hum Vaccin Immunother. 2022 Dec 31;18(1):1-6. doi: 10.1080/21645515.2021.1963171. Epub 2021 Aug 26. Hum Vaccin Immunother. 2022. PMID: 34435938 Free PMC article.
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous